Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
तुलना करने के लिए मीट्रिक्स | MIST | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMISTपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.8x | −0.9x | −0.5x | |
PEG अनुपात | −0.03 | −0.02 | 0.00 | |
क़ीमत/बुक | 5.6x | 0.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.2x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 260.4% | 343.1% | 53.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.7% | 10.2% | अनलॉक करें |